Nuveen’s Opus Genetics IRD Stock Holding History

Nuveen’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$558K	Buy	115,361 +44,018	+62%	+$183K	﹤0.01%	3319
2026 Q2	$293K	Buy	+71,343	New	+$333K	﹤0.01%	3511

Other funds holding IRD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Texas Capital Bank Wealth Management Services Dallas, Texas $1.94B AUM 19.18% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Nuveen's IRD Position: Q3 2026 in Review

Nuveen increased its Opus Genetics (IRD) stake by 62% in Q3 2026, buying an estimated $183K and bringing the position to 115,361 shares worth $558K. The position accounts for ﹤0.01% of the portfolio, ranked #3319.

Nuveen first reported a position in IRD in Q2 2026 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

Nuveen held 115,361 shares of Opus Genetics worth $558K as of Q3 2026.
Nuveen bought 44,018 Opus Genetics shares in Q3 2026, an estimated $183K.
Opus Genetics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #3319 holding.
Nuveen first reported a position in Opus Genetics in Q2 2026 and has held it in 2 quarters since.
41 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.